It is 20% of 2019 performance. Aristo is a 3 million AUD EBITDA per quarter asset.
It will be a good sign if the group can recover to 4.5-5 million per quarter by end of this quarter
It will be on more solid footing when cash balance reaching 30 million AUD, which is enough to cover the loans and the potential tax liabilities.
Don't see that happening for another 12 months to be frank.
So I don't see there will be major rerating over the peak since covid
It is 20% of 2019 performance. Aristo is a 3 million AUD EBITDA...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DNA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.76M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 80421 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.5¢ | 666873 | 2 |
View Market Depth
| Last trade - 16.12pm 21/06/2024 (20 minute delay) ? |
| DNA (ASX) Chart |
Day chart unavailable